On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The company offers Enhertu to treat patients with HER2 positive ... a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors ...

The company offers Enhertu to treat patients with HER2 positive ... a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors ...

In contrast, EsoBiotec's ENaBL technology allows the cells to be administered through a simple intravenous injection without ... antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan ...

Risdiplam is an orally-active liquid taken once-daily, while Spinraza is given by intrathecal injection into the spine ... antibody-drug conjugate (ADC) Enhertu an option for previously untreated ...

BESREMi (Ropeginterferon alfa-2b-njft) Injection There is a critical shortage of PEGASYS ... For the most up-to-date information, consult Health Canada's NOC database. Enhertu (trastuzumab deruxtecan) ...

Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line treatment in HER2-positive breast cancer after recording “highly ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) with pertuzumab has shown progression-free survival (PFS) improvement in the Phase III DESTINY-Breast09 trial, when used as a ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in patients with HER2-positive ...